Business Context and Reporting Period
Company: Protagonist Therapeutics, Inc. (PTGX)
Filing Type: Form 8-K (Current Report)
Date of Report: July 4, 2023
Reporting Period: Event date July 4, 2023; Signed July 5, 2023
The Company is a clinical-stage biopharmaceutical company focused on developing novel therapeutics. This filing serves to disseminate an updated corporate presentation containing new clinical trial data and timelines.
Key Financial Metrics
This Form 8-K does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity metrics. The filing is limited to the disclosure of a corporate presentation update.
Material Changes
The filing discloses the release of an updated corporate presentation (Exhibit 99.1) containing the following material updates:
- Phase 2b FRONTIER 1 Trial: Additional information regarding the trial of JNJ-2113 in patients with moderate-to-severe plaque psoriasis.
- Phase 3 VERIFY Trial: Updated timing for expected enrollment completion for rusfertide in patients with polycythemia vera.
Guidance, Outlook, and Risks
Outlook: The filing provides updated enrollment completion timelines for the Phase 3 VERIFY trial, which serves as a forward-looking indicator for the rusfertide program. Specific guidance numbers are not detailed in the text of the 8-K but are referenced within the attached presentation.
Risks and Contingencies: The filing text does not explicitly list new risks or contingencies beyond the standard implications of clinical trial progress. As an emerging growth company, the registrant has elected not to use the extended transition period for complying with new or revised financial accounting standards.
Investor Verification Checklist
- Review Exhibit 99.1 (Corporate Presentation) for specific data points on the JNJ-2113 Phase 2b FRONTIER 1 trial results.
- Verify the specific dates provided for the expected enrollment completion of the Phase 3 VERIFY trial in the attached presentation.
- Confirm the status of the Company's cash runway and liquidity in the most recent 10-Q or 10-K, as this 8-K does not provide financial data.